journal article·2019-05-02Open access

Material design for lymph node drug delivery

Alex Schudel, David M. Francis, Susan N. Thomas

Nature Reviews Materials· Volume 4· Issue 6

Abstract

A significant fraction of the total immune cells in the body are located in several hundred lymph nodes, in which lymphocyte accumulation, activation and proliferation are organized. Therefore, targeting lymph nodes provides the possibility to directly deliver drugs to lymphocytes and lymph node-resident cells and thus to modify the adaptive immune response. However, owing to the structure and anatomy of lymph nodes, as well as the distinct localization and migration of the different cell types within the lymph node, it is difficult to access specific cell populations by delivering free drugs. Materials can be used as instructive delivery vehicles to achieve accumulation of drugs in the lymph nodes and to target specific lymph node-resident cell subtypes. In this Review, we describe the compartmental architecture of lymph nodes and the cell and fluid transport mechanisms to and from lymph nodes. We discuss the different entry routes into lymph nodes and how they can be explored for drug delivery, including the lymphatics, blood capillaries, high endothelial venules, cell-mediated pathways, homing of circulating lymphocytes and direct lymph node injection. We examine different nanoscale and microscale materials for the targeting of specific immune cells and highlight their potential for the treatment of immune dysfunction and for cancer immunotherapy. Finally, we give an outlook to the field, exploring how lymph node targeting can be improved by the use of materials.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · CAR-T cell therapy research · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Sainte-Marie, G. The lymph node revisited: development, morphology, functioning, and role in triggering primary immune responses. Anat. Rec. 293, 320–337 (2010).10.1002/ar.21051 ↗
2. Kaldjian, E. P., Gretz, J. E., Anderson, A. O., Shi, Y. & Shaw, S. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int. Immunol. 13, 1243–1253 (2001).10.1093/intimm/13.10.1243 ↗
3. Chaplin, D. D. Overview of the immune response. J. Allergy Clin. Immunol. 125, S3–S23 (2010).10.1016/j.jaci.2009.12.980 ↗
4. Murphy, K., Travers, P., Walport, M. & Janeway, C. Janeway’s Immunobiology 8th edn (Garland Science, 2012).
5. Jeanbart, L. et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol. Res. 2, 436–447 (2014).10.1158/2326-6066.CIR-14-0019-T ↗
6. Kourtis, I. C. et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLOS ONE 8, e61646 (2013).10.1371/journal.pone.0061646 ↗
7. Schudel, A., Sestito, L. F. & Thomas, S. N. Winner of the society for biomaterials young investigator award for the annual meeting of the society for biomaterials, April 11–14, 2018, Atlanta, GA: S-nitrosated poly(propylene sulfide) nanoparticles for enhanced nitric oxide delivery to lymphatic tissues. J. Biomed. Mater. Res. A 106, 1463–1475 (2018).10.1002/jbm.a.36348 ↗
8. Keller, S. et al. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. J. Control. Release 191, 24–33 (2014).10.1016/j.jconrel.2014.03.041 ↗
9. Foster, S., Duvall, C. L., Crownover, E. F., Hoffman, A. S. & Stayton, P. S. Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T cell production and prophylactic vaccine efficacy. Bioconjug. Chem. 21, 2205–2212 (2010).10.1021/bc100204m ↗
10. Leleux, J. A., Pradhan, P. & Roy, K. Biophysical attributes of CpG presentation control TLR9 signaling to differentially polarize systemic immune responses. Cell Rep. 18, 700–710 (2017).10.1016/j.celrep.2016.12.073 ↗
11. Kaminskas, L. M. et al. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. J. Control. Release 140, 108–116 (2009).10.1016/j.jconrel.2009.08.005 ↗
12. Ryan, G. M. et al. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. J. Control. Release 172, 128–136 (2013).10.1016/j.jconrel.2013.08.004 ↗
13. An, M., Li, M., Xi, J. & Liu, H. Silica nanoparticle as a lymph node targeting platform for vaccine delivery. ACS Appl. Mater. Interfaces 9, 23466–23475 (2017).10.1021/acsami.7b06024 ↗
14. Kang, S. et al. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J. Control. Release 256, 56–67 (2017).10.1016/j.jconrel.2017.04.024 ↗
15. Wang, C. et al. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory. Vaccine 32, 5475–5483 (2014).10.1016/j.vaccine.2014.07.081 ↗
16. Delemarre, F. G., Kors, N., Kraal, G. & van Rooijen, N. Repopulation of macrophages in popliteal lymph nodes of mice after liposome-mediated depletion. J. Leukoc. Biol. 47, 251–257 (1990).10.1002/jlb.47.3.251 ↗
17. Singh, I., Swami, R., Khan, W. & Sistla, R. Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin. Drug Deliv. 11, 211–229 (2014).10.1517/17425247.2014.866088 ↗
18. Nune, S. K., Gunda, P., Majeti, B. K., Thallapally, P. K. & Forrest, M. L. Advances in lymphatic imaging and drug delivery. Adv. Drug Delivery Rev. 63, 876–885 (2011).10.1016/j.addr.2011.05.020 ↗
19. Tacken, P. J., de Vries, I. J., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790–802 (2007).10.1038/nri2173 ↗
20. Gray, E. E. & Cyster, J. G. Lymph node macrophages. J. Innate Immun. 4, 424–436 (2012).10.1159/000337007 ↗
21. Ahsan, F., Rivas, I. P., Khan, M. A. & Torres Suarez, A. I. Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J. Control. Release 79, 29–40 (2002).10.1016/S0168-3659(01)00549-1 ↗
22. Lederman, M. M. & Margolis, L. The lymph node in HIV pathogenesis. Semin. Immunol. 20, 187–195 (2008).10.1016/j.smim.2008.06.001 ↗
23. Thomas, S. N., Rohner, N. A. & Edwards, E. E. Implications of lymphatic transport to lymph nodes in immunity and immunotherapy. Annu. Rev. Biomed. Engineer. 18, 207–233 (2016).10.1146/annurev-bioeng-101515-014413 ↗
24. Rohner, N. A. et al. Lymph node biophysical remodeling is associated with melanoma lymphatic drainage. FASEB J. 29, 4512–4522 (2015).10.1096/fj.15-274761 ↗
25. Pereira, E. R., Jones, D., Jung, K. & Padera, T. P. The lymph node microenvironment and its role in the progression of metastatic cancer. Semin. Cell Dev. Biol. 38, 98–105 (2015).10.1016/j.semcdb.2015.01.008 ↗
26. Miyaji, K. et al. The stiffness of lymph nodes containing lung carcinoma metastases: a new diagnostic parameter measured by a tactile sensor. Cancer 80, 1920–1925 (1997).10.1002/(SICI)1097-0142(19971115)80:10<1920::AID-CNCR8>3.0.CO;2-R ↗
27. Chung, M. K. et al. Lymphatic vessels and high endothelial venules are increased in the sentinel lymph nodes of patients with oral squamous cell carcinoma before the arrival of tumor cells. Ann. Surg. Oncol. 19, 1595–1601 (2012).10.1245/s10434-011-2154-9 ↗
28. Nathanson, S. D. & Mahan, M. Sentinel lymph node pressure in breast cancer. Ann. Surg. Oncol. 18, 3791–3796 (2011).10.1245/s10434-011-1796-y ↗
29. Nathanson, S. D., Shah, R., Chitale, D. A. & Mahan, M. Intraoperative clinical assessment and pressure measurements of sentinel lymph nodes in breast cancer. Ann. Surg. Oncol. 21, 81–85 (2014).10.1245/s10434-013-3249-2 ↗
30. Qian, C. N. et al. Preparing the “soil”: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 66, 10365–10376 (2006).10.1158/0008-5472.CAN-06-2977 ↗
31. Willard-Mack, C. L. Normal structure, function, and histology of lymph nodes. Toxicol. Pathol. 34, 409–424 (2006).10.1080/01926230600867727 ↗
32. Kelly, R. H. Functional anatomy of lymph nodes. I. The paracortical cords. Int. Arch. Allergy Appl. Immunol. 48, 836–849 (1975).10.1159/000231371 ↗
33. Forkert, P. G., Thliveris, J. A. & Bertalanffy, F. D. Structure of sinuses in the human lymph node. Cell Tissue Res. 183, 115–130 (1977).10.1007/BF00219996 ↗
34. Gretz, J. E., Kaldjian, E. P., Anderson, A. O. & Shaw, S. Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. J. Immunol. 157, 495–499 (1996).10.4049/jimmunol.157.2.495 ↗
35. Gretz, J. E., Anderson, A. O. & Shaw, S. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol. Rev. 156, 11–24 (1997).10.1111/j.1600-065X.1997.tb00955.x ↗
36. MacLennan, I. C. Germinal centers. Annu. Rev. Immunol. 12, 117–139 (1994).10.1146/annurev.iy.12.040194.001001 ↗
37. Kroese, F. G., Timens, W. & Nieuwenhuis, P. Germinal center reaction and B lymphocytes: morphology and function. Curr. Top. Pathol. 84, 103–148 (1990).10.1007/978-3-642-75519-4_5 ↗
38. Romani, N. et al. Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, regulation, and relevance. Int. Rev. Cytol. 207, 237–270 (2001).10.1016/S0074-7696(01)07007-3 ↗
39. Belisle, C. & Sainte-Marie, G. Tridimensional study of the deep cortex of the rat lymph node. III. Morphology of the deep cortex units. Anat. Rec. 199, 213–226 (1981).10.1002/ar.1091990206 ↗
40. Girard, J. P., Moussion, C. & Forster, R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol. 12, 762–773 (2012).10.1038/nri3298 ↗
41. Randolph, G. J., Ivanov, S., Zinselmeyer, B. H. & Scallan, J. P. The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017).10.1146/annurev-immunol-041015-055354 ↗
42. Baluk, P. et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 204, 2349–2362 (2007).10.1084/jem.20062596 ↗
43. Swartz, M. A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50, 3–20 (2001).10.1016/S0169-409X(01)00150-8 ↗
44. Schmid-Schonbein, G. W. Mechanisms causing initial lymphatics to expand and compress to promote lymph flow. Arch. Histol Cytol. 53 (Suppl), 107–114 (1990).10.1679/aohc.53.Suppl_107 ↗
45. Kastenmuller, W., Torabi-Parizi, P., Subramanian, N., Lammermann, T. & Germain, R. N. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 150, 1235–1248 (2012).10.1016/j.cell.2012.07.021 ↗
46. Rantakari, P. et al. The endothelial protein PLVAP in lymphatics controls the entry of lymphocytes and antigens into lymph nodes. Nat. Immunol. 16, 386–396 (2015).10.1038/ni.3101 ↗
47. Roozendaal, R. et al. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30, 264–276 (2009).10.1016/j.immuni.2008.12.014 ↗
48. Gretz, J. E., Norbury, C. C., Anderson, A. O., Proudfoot, A. E. & Shaw, S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J. Exp. Med. 192, 1425–1440 (2000).10.1084/jem.192.10.1425 ↗
49. Sixt, M. et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22, 19–29 (2005).10.1016/j.immuni.2004.11.013 ↗
50. Thomas, S. N. & Schudel, A. Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery. Curr. Opin. Chem. Eng. 7, 65–74 (2015).10.1016/j.coche.2014.11.003 ↗
51. Rohner, N. A. & Thomas, S. N. Flexible macromolecule versus rigid particle retention in the injected skin and accumulation in draining lymph nodes are differentially influenced by hydrodynamic size. ACS Biomater. Sci. Eng. 3, 153–159 (2017).10.1021/acsbiomaterials.6b00438 ↗
52. Stroh, M. et al. Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion. Nat. Mater. 3, 489–494 (2004).10.1038/nmat1159 ↗
53. Reddy, S. T., Berk, D. A., Jain, R. K. & Swartz, M. A. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J. Appl. Physiol. 101, 1162–1169 (2006).10.1152/japplphysiol.00389.2006 ↗
54. Rohner, N. A. & Thomas, S. N. Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes. J. Control. Release 223, 99–108 (2016). This study details quantification of the relative efficiency of nanocarrier versus microcarrier accumulation within lymph nodes versus systemic tissues after administration in the periphery and investigation of the effects of disease on the extent of specific targeting.10.1016/j.jconrel.2015.12.027 ↗
55. Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A. & Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112, 26–34 (2006).10.1016/j.jconrel.2006.01.006 ↗
56. Rao, D. A., Forrest, M. L., Alani, A. W., Kwon, G. S. & Robinson, J. R. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J. Pharm. Sci. 99, 2018–2031 (2010).10.1002/jps.21970 ↗
57. Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489–496 (2017).10.1038/nmat4822 ↗
58. Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17, 302–317 (2017).10.1038/nrc.2017.6 ↗
59. Srinivasan, S., Vannberg, F. O. & Dixon, J. B. Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016).10.1038/srep24436 ↗
60. Reddy, S. T., Swartz, M. A. & Hubbell, J. A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27, 573–579 (2006).10.1016/j.it.2006.10.005 ↗
61. Sunshine, J. C., Perica, K., Schneck, J. P. & Green, J. J. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials 35, 269–277 (2014).10.1016/j.biomaterials.2013.09.050 ↗
62. Wibroe, P. P. et al. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat. Nanotechnol. 12, 589–594 (2017).10.1038/nnano.2017.47 ↗
63. Kumar, S., Anselmo, A. C., Banerjee, A., Zakrewsky, M. & Mitragotri, S. Shape and size-dependent immune response to antigen-carrying nanoparticles. J. Control. Release 220, 141–148 (2015).10.1016/j.jconrel.2015.09.069 ↗
64. Ryan, G. M. et al. A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheep. Pharm. Res. 33, 510–525 (2016).10.1007/s11095-015-1806-z ↗
65. Agarwal, R. et al. Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms. Proc. Natl Acad. Sci. USA 110, 17247–17252 (2013).10.1073/pnas.1305000110 ↗
66. Foged, C., Brodin, B., Frokjaer, S. & Sundblad, A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298, 315–322 (2005).10.1016/j.ijpharm.2005.03.035 ↗
67. Thomas, S. N., Vokali, E., Lund, A. W., Hubbell, J. A. & Swartz, M. A. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 35, 814–824 (2014). This study provides a demonstration of the principle and therapeutic benefit of lymph node targeting using lymphatic-draining nanoparticles in mediating delivery of immune-stimulatory small molecule adjuvants to tumour-draining lymph nodes to potentiate adaptive immune responses against endogenously produced tumour antigen co-draining to targeted lymph nodes.10.1016/j.biomaterials.2013.10.003 ↗
68. Rehor, A., Hubbell, J. A. & Tirelli, N. Oxidation-sensitive polymeric nanoparticles. Langmuir 21, 411–417 (2005).10.1021/la0478043 ↗
69. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014). This study details the engineering of a modified subunit vaccine, specifically a lipid-modified peptide and adjuvant oligonucleotide CpG that leverage endogenous albumin transport of hydrophobic lipids to the lymph node to improve vaccine effects.10.1038/nature12978 ↗
70. Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2017). This paper details an investigation of a variety of liposomal formulations to achieve high mRNA encapsulation and cytosolic delivery to APCs for mRNA vaccines, achieving high transfection rates at the site of injection and in the draining lymph node.10.1021/acs.nanolett.6b03329 ↗
71. Karabin, N. B. et al. Sustained micellar delivery via inducible transitions in nanostructure morphology. Nat. Commun. 9, 624 (2018).10.1038/s41467-018-03001-9 ↗
72. Nuhn, L. et al. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proc. Natl Acad. Sci. USA 113, 8098–8103 (2016).10.1073/pnas.1600816113 ↗
73. Zhang, F., Zhu, L., Huang, X., Niu, G. & Chen, X. Differentiation of reactive and tumor metastatic lymph nodes with diffusion-weighted and SPIO-enhanced MRI. Mol. Imaging Biol. 15, 40–47 (2013).10.1007/s11307-012-0562-2 ↗
74. Liang, C. et al. Tumor metastasis inhibition by imaging-guided photothermal therapy with single-walled carbon nanotubes. Adv. Mater. 26, 5646–5652 (2014).10.1002/adma.201401825 ↗
75. Oladipo, A. O. et al. A novel treatment for metastatic lymph nodes using lymphatic delivery and photothermal therapy. Sci. Rep. 7, 45459 (2017).10.1038/srep45459 ↗
76. Gonzalez, S. F., Pitcher, L. A., Mempel, T., Schuerpf, F. & Carroll, M. C. B cell acquisition of antigen in vivo. Curr. Opin. Immunol. 21, 251–257 (2009).10.1016/j.coi.2009.05.013 ↗
77. Catron, D. M., Pape, K. A., Fife, B. T., van Rooijen, N. & Jenkins, M. K. A protease-dependent mechanism for initiating T-dependent B cell responses to large particulate antigens. J. Immunol. 184, 3609–3617 (2010).10.4049/jimmunol.1000077 ↗
78. Heyman, B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18, 709–737 (2000).10.1146/annurev.immunol.18.1.709 ↗
79. Phan, T. G., Grigorova, I., Okada, T. & Cyster, J. G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 8, 992–1000 (2007).10.1038/ni1494 ↗
80. Phan, T. G., Green, J. A., Gray, E. E., Xu, Y. & Cyster, J. G. Immune complex relay by subcapsular sinus macrophages and non-cognate B cells drives antibody affinity maturation. Nat. Immunol. 10, 786–793 (2009).10.1038/ni.1745 ↗
81. Gonzalez, S. F. et al. Complement-dependent transport of antigen into B cell follicles. J. Immunol. 185, 2659–2664 (2010).10.4049/jimmunol.1000522 ↗
82. Heesters, B. A. et al. Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 38, 1164–1175 (2013).10.1016/j.immuni.2013.02.023 ↗
83. Roozendaal, R. & Carroll, M. C. Complement receptors CD21 and CD35 in humoral immunity. Immunol. Rev. 219, 157–166 (2007).10.1111/j.1600-065X.2007.00556.x ↗
84. Junt, T. et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450, 110–114 (2007).10.1038/nature06287 ↗
85. Carrasco, Y. R. & Batista, F. D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27, 160–171 (2007).10.1016/j.immuni.2007.06.007 ↗
86. Pucci, F. et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352, 242–246 (2016).10.1126/science.aaf1328 ↗
87. Saunderson, S. C., Dunn, A. C., Crocker, P. R. & McLellan, A. D. CD169 mediates the capture of exosomes in spleen and lymph node. Blood 123, 208–216 (2014).10.1182/blood-2013-03-489732 ↗
88. Bernhard, C. A., Ried, C., Kochanek, S. & Brocker, T. CD169+macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells. Proc. Natl Acad. Sci. USA 112, 5461–5466 (2015).10.1073/pnas.1423356112 ↗
89. van Rooijen, N. & Hendrikx, E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol. Biol. 605, 189–203 (2010).10.1007/978-1-60327-360-2_13 ↗
90. Hettiaratchi, M. H. et al. A rapid method for determining protein diffusion through hydrogels for regenerative medicine applications. APL Bioeng. 2, 026110 (2018).10.1063/1.4999925 ↗
91. van Rooijen, N. & van Kesteren-Hendrikx, E. Clodronate liposomes: perspectives in research and therapeutics. J. Liposome Res. 12, 81–94 (2002).10.1081/LPR-120004780 ↗
92. Bahmani, B. et al. Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival. J. Clin. Invest. 128, 4770–4786 (2018). This paper shows that intravenously administered nanoparticles carrying therapeutic anti-CD3 monoclonal antibodies are directed to lymph nodes via targeting of high endothelial venules with an anti-MECA-79 monoclonal antibody to prolong cardiac allograft survival compared with unmodified, drug-laden nanoparticles or free drug.10.1172/JCI120923 ↗
93. Azzi, J. et al. Targeted delivery of immunomodulators to lymph nodes. Cell Rep. 15, 1202–1213 (2016). This paper exploits the same targeting methods used in the work by Bahmani et al. (directed delivery to adhesive ligand that T cells use to home to the lymph node) using microparticles encapsulating immunomodulators to improve allograft survival.10.1016/j.celrep.2016.04.007 ↗
94. Cabral, H. et al. Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers. ACS Nano 9, 4957–4967 (2015). This paper describes the investigation of the effects of the size of sub-100 nm nanoparticles on lymph node accumulation versus delivery to lymph node-localized metastatic tumour foci to improve antitumour therapeutic effects.10.1021/nn5070259 ↗
95. Zheng, Y. et al. In vivo targeting of adoptively transferred T cells with antibody- and cytokine-conjugated liposomes. J. Control. Release 172, 426–435 (2013).10.1016/j.jconrel.2013.05.037 ↗
96. Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241–254 (2005).10.1016/j.ccr.2005.08.010 ↗
97. Kissenpfennig, A. et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643–654 (2005).10.1016/j.immuni.2005.04.004 ↗
98. Lutz, M. B. & Schuler, G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23, 445–449 (2002).10.1016/S1471-4906(02)02281-0 ↗
99. Joffre, O., Nolte, M. A., Sporri, R. & Reis e Sousa, C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227, 234–247 (2009).10.1111/j.1600-065X.2008.00718.x ↗
100. Gallo, P. M. & Gallucci, S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 4, 138 (2013).10.3389/fimmu.2013.00138 ↗